Workflow
内部控制缺陷
icon
Search documents
大连百傲化学股份有限公司 关于收到大连证监局行政监管措施决定书的公告
上述行为违反了《上市公司治理准则(2018年修订)》(证监会公告〔2018〕29号,以下简称《治理准 则》)第七十一条第一款的规定,违反了《企业内部控制应用指引第6号--资金活动》第二十一条第三 款,《企业内部控制应用指引第7号--采购业务》第四条和第十三条第一款、第三款、第四款,《企业 内部控制应用指引第16号--合同管理》第十四条、第十六条的规定。公司董事长刘宪武、财务总监王希 梁,违反了《治理准则》第四条的规定,对上述事项负有主要责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 大连百傲化学股份有限公司(以下简称"公司")于2025年8月14日收到中国证券监督管理委员会大连监 管局下发的《关于对大连百傲化学股份有限公司采取责令改正措施并对刘宪武、王希梁采取出具警示函 措施的决定》(行政监管措施〔2025〕16号),现将原文内容公告如下: "大连百傲化学股份有限公司、刘宪武、王希梁: 经查,大连百傲化学股份有限公司(以下简称公司)内部控制存在缺陷。 一是公司及原全资子 ...
ST长园: 关于上交所对公司2024年年度报告的信息披露监管问询函的回复公告
Zheng Quan Zhi Xing· 2025-07-10 16:21
Core Viewpoint - The company, Changyuan Technology Group Co., Ltd., is under scrutiny from the Shanghai Stock Exchange regarding its 2024 annual report due to issues related to non-operating fund occupation by related parties, leading to significant internal control deficiencies and accounting errors [1][2][3]. Group 1: Related Party Fund Occupation - The company’s chairman, Wu Qiquan, is linked to Zhuhai Yuntaili Holdings Co., Ltd., which has been identified as occupying company funds through third parties [1][2]. - The annual audit revealed that the auditors could not obtain sufficient evidence to identify all related parties, resulting in a qualified opinion on the financial statements [1][3]. - The company has acknowledged the need to correct accounting errors related to non-operating fund occupation in its financial reports for 2023 and 2024 [1][3]. Group 2: Supplier Information and Financial Data - The company identified seven suppliers involved in fund occupation, detailing their establishment dates, major financial data, and actual controllers [2][3][4]. - For example, Zhuhai Chengbangda has total assets of 261.73 million yuan and a net profit of 5.5 million yuan as of December 31, 2024 [3][4]. - The company has initiated self-inspections and requested confirmations from these suppliers regarding their actual controllers and any potential fund occupation [4][5]. Group 3: Internal Control Deficiencies - The company has recognized significant internal control deficiencies in its fund payment approval and related party transaction processes [1][2][3]. - Contracts and payments related to the identified suppliers were executed without proper authorization, leading to difficulties in detecting fund occupation [1][2][3]. - The company plans to implement corrective measures and hold responsible personnel accountable for these deficiencies [2][3][5]. Group 4: Financial Adjustments and Reporting - The company has made retrospective adjustments to its financial statements for the years 2023 and 2024 to reflect the impact of the identified accounting errors [1][2][3]. - The adjustments include changes to monetary funds, other receivables, and credit impairment losses [1][2][3]. - The company has committed to adhering to accounting standards and ensuring timely disclosures of any further adjustments needed [1][2][3].
ST华西五年亏24亿内控存缺陷 黎仁超被留置并立案股份全部冻结
Chang Jiang Shang Bao· 2025-05-21 23:47
Core Viewpoint - The sudden resignation and subsequent detention of Li Renchao, the controlling shareholder and actual controller of ST Huaxi, raises concerns about the company's governance and operational stability, especially given its ongoing financial struggles and history of losses [1][2][5]. Group 1: Company Events - On May 20, ST Huaxi announced that it received a detention notice for Li Renchao from the local supervisory committee, just hours after he resigned from his positions as director, chairman, and president due to personal reasons [1][2]. - Li Renchao's shares in ST Huaxi, totaling 149 million shares, have been completely frozen, representing 12.62% of the company's total shares [3][5]. - The company stated that its board of directors and management are functioning normally and that the operational activities will not be significantly impacted by these events [2][5]. Group 2: Financial Performance - In 2024, ST Huaxi reported revenues of 2.593 billion yuan, a year-on-year increase of 38.91%, but incurred a net loss of 348 million yuan, a reduction in losses by 80.37% compared to the previous year [5][6]. - The company has faced continuous losses for five consecutive years, with cumulative net losses amounting to approximately 2.446 billion yuan [6][7]. - The internal control audit for 2024 received an adverse opinion, leading to the stock being placed under risk warning since April 30, with its name changed to ST Huaxi [6][7]. Group 3: Governance and Compliance Issues - The independent director raised concerns about significant deficiencies in internal controls related to procurement, payment processes, and project settlements, which have not been adequately addressed [6][7]. - ST Huaxi is actively working on rectifying the issues highlighted in the internal control audit report, aiming to lift the ST designation from its stock [7].
ST华西实际控制人被留置 三天前公司已收到他的书面辞职报告
Mei Ri Jing Ji Xin Wen· 2025-05-20 15:44
Core Viewpoint - ST Huaxi (002630.SZ) announced the resignation of its controlling shareholder and actual controller, Li Renchao, following a notice of detention and case filing from the supervisory committee of a district in Suining City. Li is no longer in any position within the company or its subsidiaries, and the company’s operations remain normal despite this leadership change [1][2][3]. Group 1 - The company disclosed that Li Renchao submitted his resignation on May 17, 2024, and the board expressed gratitude for his service [2][3]. - Li Renchao, aged 61, has been with the company since November 2007, serving as chairman and later as president. He has held various positions in other companies, including as chairman of Huaxi Energy Industrial Group [2][4]. - The company’s board of directors and management are functioning normally, and there has been no change in control or significant impact on operations [2][3]. Group 2 - The last board meeting chaired by Li Renchao was on March 13, 2024, with subsequent meetings led by the newly elected chairman, Huang Youquan [4]. - Huang Youquan, who is also 61 years old, has been a director since November 2020 and was appointed chairman and president on May 19, 2024 [4]. - The board has approved various reports, including the 2024 annual report and internal control self-evaluation report, although there was one abstention vote during the meetings [4]. Group 3 - Independent director Xie Xinglong raised concerns about significant deficiencies in internal controls, particularly regarding procurement and payment processes, which were acknowledged but not fully addressed [5]. - The audit firm provided a "non-standard" opinion on the company's 2023 annual report and internal control report, highlighting issues raised by Xie [5][6]. - Specific procurement issues were noted, including a prepayment of 34.0973 million yuan for idle materials that were later deemed unnecessary for the project [6].
内控存在重大缺陷,葫芦娃股票明起变更为“ST葫芦娃”
Bei Ke Cai Jing· 2025-04-29 14:45
Core Viewpoint - Hainan Huhuwawa Pharmaceutical Group Co., Ltd. faces significant internal control issues, leading to a negative audit opinion and a stock trading suspension, with a change in stock abbreviation to "ST Huhuwawa" starting April 30, 2025 [1][3][5] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.414 billion yuan, a year-on-year decrease of 21.26%, and a net profit attributable to shareholders of -274 million yuan, a staggering decline of 2629.23% [10] - In the first quarter of 2025, the company achieved a revenue of 337 million yuan, down 28.42% year-on-year, with a net profit of approximately 24.35 million yuan, a decrease of 11.23% [10] Internal Control Issues - The audit report from Lixin Certified Public Accountants highlighted three major areas of concern regarding internal controls, including the lack of complete financial data related to restated financial statements and issues with accounts receivable from key clients [3][5] - The company has been criticized for significant deficiencies in its internal control over financial reporting, resulting in a negative opinion from the auditors [5] Management Changes - The company's general manager, Zhang Mingrui, resigned for personal reasons less than two months after taking office, marking a period of instability in leadership [2][6] - This resignation follows the earlier departure of Liu Jingping from the general manager position, who remains as chairman and has been a key figure in the company since its inception [7][8] Related Transactions - In 2024, the company purchased eight R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for 42.0537 million yuan, raising concerns due to familial ties between the company's actual controller and the legal representative of the vendor [4]